SCHEMBL4865203

SCHEMBL4865203

O=C(CCBr)Nc1cccc2c1CCC2

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.70
LMNA P02545 4/20 0.70
MEN1 O00255 4/20 0.70
KMT2A Q03164 4/20 0.70
THRA P10827 1/20 0.70
THRB P10828 1/20 0.70
KDM4E B2RXH2 2/20 0.56
POLB P06746 1/20 0.56
L3MBTL1 Q9Y468 4/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
TSHR P16473 3/20 0.51
CYP3A4 P08684 2/20 0.50
CYP2C19 P33261 2/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2D6 P10635 1/20 0.50
HPGD P15428 1/20 0.50
ATM Q13315 1/20 0.50
RXRA P19793 1/20 0.48
RXRB P28702 1/20 0.48
RXRG P48443 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4005306 0.85 ALDH1A1 (0.71) ALDH1A1LMNAMEN1KMT2ATHRA
SCHEMBL10800952 0.82 MEN1 (0.74) ALDH1A1LMNAMEN1KMT2ATHRA
SCHEMBL30514209 0.82 ALDH1A1 (0.67) ALDH1A1LMNAMEN1KMT2ATHRA
SCHEMBL4866699 0.82 ALDH1A1 (0.67) ALDH1A1LMNAMEN1KMT2ATHRA
SCHEMBL28404830 0.82 LMNA (0.78) ALDH1A1LMNAMEN1KMT2ATHRA
SCHEMBL3014533 0.81 ALDH1A1 (0.65) ALDH1A1LMNAMEN1KMT2ATHRA
SCHEMBL4858016 0.79 ALDH1A1 (0.71) ALDH1A1LMNAMEN1KMT2ATHRA
SCHEMBL3066269 0.79 ALDH1A1 (0.78) ALDH1A1LMNAMEN1KMT2ATHRA
SCHEMBL19305874 0.78 ALDH1A1 (0.60) ALDH1A1LMNAMEN1KMT2ATHRA
SCHEMBL10800631 0.77 ALDH1A1 (0.70) ALDH1A1LMNAMEN1KMT2ATHRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7407960-B2 Substituted heterocyclic compounds CV THERAPEUTICS, INC. (US) 2008-08-05 US disclosed
EP-1806346-A1 Substituted piperazine compounds and their use as fatty acid oxidation inhibitors CV THERAPEUTICS, INC. (US) 2007-07-11 EP disclosed
US-20070004751-A1 Substituted heterocyclic compounds ELZEIN ELFATIH 2007-01-04 US disclosed
US-7125876-B2 Substituted heterocyclic compounds CV THERAPEUTICS, INC. (US) 2006-10-24 US disclosed
EP-1567525-A2 SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS CV THERAPEUTICS, INC. (US) 2005-08-31 EP disclosed
US-20040152890-A1 Substituted heterocyclic compounds CV THERAPEUTICS, INC. 2004-08-05 US disclosed
WO-2004052887-A2 SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS CV THERAPEUTICS, INC. (US) 2004-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152890-A1 Substituted heterocyclic compounds KCNH1, SDHA, COQ8A ALDH1A1 245/4885LMNA 2835/4885MEN1 3200/4885
US-20070004751-A1 Substituted heterocyclic compounds KCNH1, SDHA, COQ8A ALDH1A1 281/4885LMNA 2300/4885MEN1 2899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.